Healthcare company Abbott Laboratories (ABT) said Sunday that the primary endpoint of the ACCORD study was not met.
The ACCORD study was conducted in patients with diabetes and evaluated cardiovascular outcomes in three distinct studies - glycemic control, blood pressure control and lipid control.
The primary endpoint for the study compared fenofibrate plus simvastatin to simvastatin alone on cardiovascular outcomes of heart attacks, strokes and cardiovascular death. There was no statistical difference in the primary outcome between the two treatment groups, Abbott said.
However, in a pre-specified sub-group of patients with both high triglycerides and low HDL, there was a 31% lower rate of cardiovascular events in the fibrate-plus-statin arm compared to the statin-only arm.
According to Eugene Sun, vice president, Global Pharmaceutical Development, Abbott, "The results of ACCORD Lipid were widely expected and not surprising given that two-thirds of patients in the trial would not be treated with fibrates under current guidelines...We are encouraged by the overall safety reported in the ACCORD Lipid study for fenofibrate.''
ABT closed Friday's regular trade at $54.52, down $1.02 or 1.84%, on 16.23 million shares.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.